Highlights Legend Biotech Corporation

Stocks

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-15 EDT			Pre-market 07:13:48
35.48 ^USD	-1.09%		34.25	-3.47%

06-15	Legend Biotech Says In Vivo CAR-T Candidate LB2501 Delivers Early Proof-of-Concept in Lymphoma	MT
06-14	Genscript Associate Reports Promising Phase 1 Data for LB2501 in B-Cell Lymphoma	MT

Highlights

06-14	Legend Biotech Establishes Clinical Proof-of-Concept for LB2501 in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	CI
06-02	Legend Biotech Corporation Announces Late-Breaking Oral Presentation of Initial Phase 1 in Vivo Car-T Data with Lb2501 in Non-Hodgkin Lymphoma	CI
06-01	Legend Biotech Corporation Presents First-In-Human LB2102 Results And New CARVYKTI Data At ASCO 2026	CI
05-13	Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says	MT
05-12	Legend Biotech Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	Legend Biotech Narrows Q1 Adjusted Loss as Revenue Increases	MT
05-12	Earnings Flash (LEGN) Legend Biotech Corporation Posts Q1 Adjusted Loss $0.03 per Share	MT
05-12	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q1 Revenue $305.1M, vs. FactSet Est of $306.5M	MT
03-10	Legend Biotech Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-10	Legend Biotech Adjusted Q4 Earnings, Revenue Increase	MT
03-10	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q4 Revenue $306.3M, vs. FactSet Est of $307.8M	MT
03-10	Earnings Flash (LEGN) Legend Biotech Corporation Posts Q4 Adjusted Net Income $0.01 per Share	MT
03-10	Earnings Flash (LEGN) Legend Biotech Posts Q4 Loss $0.08 a Share, vs. FactSet Est of $0.02 EPS	MT
12-08	Legend Biotech Corporation Highlights New CARVYKTI Data in Multiple Myeloma and First-In-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma	CI
11-13	Legend Biotech Corporation Celebrates Official Opening of New Cell Therapy Research and Development Facility in Philadelphia	CI
11-12	Legend Biotech Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-12	Legend Biotech Q3 Adjusted Loss Narrows, Revenue Rises	MT
11-12	Legend Biotech Q3 revenue slightly misses estimates	RE
11-12	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q3 Revenue $272.3M, vs. FactSet Est of $274.4M	MT
11-12	Earnings Flash (LEGN) Legend Biotech Corporation Posts Q3 Adjusted Loss $0.05 per Share	MT
25-10-14	Legend Biotech Corporation Announces U.S. Fda Approves Label Updates for Carvykti® Car-T Cell Therapy to Include Overall Survival Data	CI
25-10-07	Legend Biotech USA Inc. Enters into Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc	CI
25-09-05	Legend Biotech Said to Consider Second Listing Outside US	MT
25-09-05	Legend Biotech Said to Consider Second Listing Outside US, Bloomberg Reports	MT
25-08-11	Legend Biotech Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI